Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2019-05-09 Annual Report
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
2018 Annual Report
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2018' and contains comprehensive financial statements (Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity) for the fiscal year 2018. It includes a Director's Report, management commentary on group results, and notes to the financial statements, which are characteristic of a full annual report filing. FY 2018
2019-05-09 English
2018 Annual Report
Report Publication Announcement Classification · 100% confidence The document explicitly states it is the '2018 Annual Report' and mentions that the Board has approved it. However, the document text is very short (650 characters) and primarily serves to announce that the Annual Report is 'enclosed' and available online. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report is attached or published should be classified as a Report Publication Announcement (RPA), rather than the full report itself (10-K). Although the content is about the Annual Report, the document's function here is the announcement of its publication.
2019-05-09 English
First Quarter Financial Report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first quarter of 2019 (1Q19) for Gentian Diagnostics AS. It includes detailed financial statements such as the Statement of Comprehensive Income, Statement of Financial Position, and Cash Flow Statement, along with management commentary on operational status, R&D, and outlook. It is not an announcement of a report, but the report itself, and contains substantive financial data, fitting the definition of an Interim/Quarterly Report. Q1 2019
2019-05-09 English
First Quarter Financial Report
Investor Presentation Classification · 98% confidence The document is titled 'Q1 Presentation 2019' and contains slides detailing financial highlights for Q1 2019 (Sales, Revenues, EBITDA, Cash Flow), market analysis, product updates (Cystatin C, fCAL turbo, GCAL), and an outlook for the rest of the year. This structure is characteristic of an Investor Presentation (IP) used to communicate periodic performance and strategy to investors, rather than a full regulatory report (like 10-K or IR) or a brief earnings release (ER). The presence of detailed slides, agenda, and forward-looking statements strongly supports the classification as an Investor Presentation.
2019-05-09 English
First Quarter Financial Report
Report Publication Announcement Classification · 98% confidence The document is titled 'First Quarter Financial Report' and explicitly announces results for the first quarter of 2018, including key financial highlights (sales revenues of MNOK 10.6). This strongly suggests an Interim/Quarterly Report (IR). However, the document is very short (948 characters) and concludes with the statement: 'Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.' According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that the full report is enclosed or published points towards a Report Publication Announcement (RPA) rather than the comprehensive report itself (IR). Since this document is announcing the publication of the Q1 report, RPA is the most appropriate classification.
2019-05-09 English
Company presentation
Investor Presentation Classification · 98% confidence The document is a presentation containing an overview of Gentian Diagnostics AS, including corporate structure, market analysis (IVD market), R&D principles, product pipeline (Cystatin C, fCAL® turbo, GCAL®), and detailed financial highlights for 2018 vs 2017. The structure, use of slides/pictures, and focus on strategy, pipeline, and financial summary strongly indicate an Investor Presentation (IP). It is not a full Annual Report (10-K), a standalone Audit Report (AR), or a brief Earnings Release (ER); it is a comprehensive deck designed for investors.
2019-04-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.